Abzena and Telix sign strategic manufacturing and bioconjugation agreement
Abzena will progress two PSMA-targeting monoclonal antibodies, currently incorporated into Telix’s PSMA radiopharmaceutical programme, for the purposes of targeted treatment of metastatic prostate cancer